For what patients/diagnoses do you currently use sodium thiosulfate to reduce the risk of cisplatin associated ototoxicity?

Sodium thiosulfate (STS) is approved in the US (FDA) and Europe (EMA) for the prevention of cisplatin-induced hearing loss (CIHL) in patients 1 month and older treated with cisplatin for any type of cancer. Although intravenous STS has not been subjected to a randomized clinical trial for patients >...